{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:09:51Z","timestamp":1782986991111,"version":"3.54.5"},"reference-count":71,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001250","name":"Morris Animal Foundation","doi-asserted-by":"publisher","award":["D22CA-500"],"award-info":[{"award-number":["D22CA-500"]}],"id":[{"id":"10.13039\/100001250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012417","name":"Colorado State University College of Veterinary Medicine and Biomedical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012417","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007235","name":"Colorado State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jpet.2025.103715","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T17:54:24Z","timestamp":1758131664000},"page":"103715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phosphatidylinositol 3-kinase and mechanistic target of rapamycin dualinhibitor, VDC597, as a therapeutic agent for canine osteosarcoma"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4094-7616","authenticated-orcid":false,"given":"Travis","family":"Meuten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0476-6575","authenticated-orcid":false,"given":"Kristen B.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Brill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5688-3872","authenticated-orcid":false,"given":"Rachel V.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Schlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-7767","authenticated-orcid":false,"given":"Douglas H.","family":"Thamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103715_bib1","series-title":"Withrow and MacEwen\u2019s Small Animal Clinical Oncology","first-page":"463","article-title":"Tumors of the skeletal system","author":"Ehrhart","year":"2013"},{"key":"10.1016\/j.jpet.2025.103715_bib2","series-title":"Tumors in Domestic Animals","first-page":"356","article-title":"Tumors of bone","author":"Thompson","year":"2017"},{"issue":"12","key":"10.1016\/j.jpet.2025.103715_bib3","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2460\/javma.228.12.1905","article-title":"Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985-2004)","volume":"228","author":"Boston","year":"2006","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"10.1016\/j.jpet.2025.103715_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2460\/javma.238.2.195","article-title":"Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996-2006)","volume":"238","author":"Saam","year":"2011","journal-title":"J Am Vet Med Assoc"},{"issue":"7","key":"10.1016\/j.jpet.2025.103715_bib5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2460\/javma.1992.200.07.995","article-title":"Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988)","volume":"200","author":"Spodnick","year":"1992","journal-title":"J Am Vet Med Assoc"},{"issue":"12","key":"10.1016\/j.jpet.2025.103715_bib6","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2460\/javma.1992.200.12.2005","article-title":"Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990)","volume":"200","author":"Berg","year":"1992","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"10.1016\/j.jpet.2025.103715_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1939-1676.1996.tb02031.x","article-title":"Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993)","volume":"10","author":"Bergman","year":"1996","journal-title":"J Vet Intern Med"},{"issue":"3","key":"10.1016\/j.jpet.2025.103715_bib8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/03009858221083038","article-title":"Canine and murine models of osteosarcoma","volume":"59","author":"Beck","year":"2022","journal-title":"Vet Pathol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103715_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tvjl.2010.08.014","article-title":"Biology, diagnosis and treatment of canine appendicular osteosarcoma: similarities and differences with human osteosarcoma","volume":"189","author":"Morello","year":"2011","journal-title":"Vet J"},{"key":"10.1016\/j.jpet.2025.103715_bib10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/1471-2164-10-625","article-title":"Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression","volume":"10","author":"Paoloni","year":"2009","journal-title":"BMC Genomics"},{"issue":"6","key":"10.1016\/j.jpet.2025.103715_bib11","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","article-title":"Role of PI3K\/AKT pathway in cancer: the framework of malignant behavior","volume":"47","author":"Jiang","year":"2020","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.jpet.2025.103715_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rvsc.2020.09.001","article-title":"PIK3CA mutations matter for cancer in dogs","volume":"133","author":"Kim","year":"2020","journal-title":"Res Vet Sci"},{"issue":"51","key":"10.1016\/j.jpet.2025.103715_bib13","doi-asserted-by":"crossref","first-page":"E5564","DOI":"10.1073\/pnas.1419260111","article-title":"Complementary genomic approaches highlight the PI3K\/mTOR pathway as a common vulnerability in osteosarcoma","volume":"111","author":"Perry","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.jpet.2025.103715_bib14","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1535-7163.MCT-18-1346","article-title":"Identifying candidate druggable targets in canine cancer cell lines using whole-exome sequencing","volume":"18","author":"Das","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.jpet.2025.103715_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.abb.2012.07.003","article-title":"Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling","volume":"526","author":"Wang","year":"2012","journal-title":"Arch Biochem Biophys"},{"issue":"2","key":"10.1016\/j.jpet.2025.103715_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246443","article-title":"Unraveling the chaotic genomic landscape of primary and metastatic canine appendicular osteosarcoma with current sequencing technologies and bioinformatic approaches","volume":"16","author":"Chu","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jpet.2025.103715_bib17","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1354\/vp.08-VP-0155-F-FL","article-title":"Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma","volume":"46","author":"Fieten","year":"2009","journal-title":"Vet Pathol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103715_bib18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.tvjl.2014.09.005","article-title":"Increased expression of insulin-like growth factor-1 receptor is correlated with worse survival in canine appendicular osteosarcoma","volume":"205","author":"Maniscalco","year":"2015","journal-title":"Vet J"},{"issue":"9","key":"10.1016\/j.jpet.2025.103715_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274383","article-title":"The genomic landscape of canine osteosarcoma cell lines reveals conserved structural complexity and pathway alterations","volume":"17","author":"Megquier","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jpet.2025.103715_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/03009858231207021","article-title":"Review: The PI3K-AKT-mTOR signal transduction pathway in canine cancer","volume":"61","author":"Meuten","year":"2024","journal-title":"Vet Pathol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103715_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011013","article-title":"Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs","volume":"5","author":"Paoloni","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jpet.2025.103715_bib22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2460\/ajvr.69.8.1079","article-title":"Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs","volume":"69","author":"Gordon","year":"2008","journal-title":"Am J Vet Res"},{"issue":"11","key":"10.1016\/j.jpet.2025.103715_bib23","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-21-0315","article-title":"Adjuvant sirolimus does not improve outcome in pet dogs receiving standard-of-care therapy for appendicular osteosarcoma: a prospective, randomized trial of 324 dogs","volume":"27","author":"LeBlanc","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jpet.2025.103715_bib24","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jpet.2025.103715_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.jpet.2025.103715_bib26","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1002\/jcp.27638","article-title":"Effects of luteolin on canine osteosarcoma: suppression of cell proliferation and synergy with cisplatin","volume":"234","author":"Ryu","year":"2019","journal-title":"J Cell Physiol"},{"issue":"10","key":"10.1016\/j.jpet.2025.103715_bib27","doi-asserted-by":"crossref","first-page":"17449","DOI":"10.1002\/jcb.29009","article-title":"Quercetin augments apoptosis of canine osteosarcoma cells by disrupting mitochondria membrane potential and regulating PKB and MAPK signal transduction","volume":"120","author":"Ryu","year":"2019","journal-title":"J Cell Biochem"},{"issue":"1","key":"10.1016\/j.jpet.2025.103715_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccell.2014.11.008","article-title":"Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2","volume":"27","author":"Schwartz","year":"2015","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.jpet.2025.103715_bib29","doi-asserted-by":"crossref","first-page":"13962","DOI":"10.18632\/oncotarget.3920","article-title":"AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1\/4E-BP1 axis","volume":"6","author":"Mi","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.jpet.2025.103715_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.canlet.2013.11.017","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate","volume":"344","author":"Gobin","year":"2014","journal-title":"Cancer Lett"},{"issue":"14","key":"10.1016\/j.jpet.2025.103715_bib31","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1158\/1078-0432.CCR-14-3026","article-title":"Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma","volume":"21","author":"Gupte","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jpet.2025.103715_bib32","doi-asserted-by":"crossref","first-page":"10483","DOI":"10.18632\/oncotarget.23711","article-title":"NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma","volume":"9","author":"Huang","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.jpet.2025.103715_bib33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/vco.12192","article-title":"The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine","volume":"15","author":"Fowles","year":"2017","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103715_bib34","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/1040638711408064","article-title":"Polymerase chain reaction-based species verification and microsatellite analysis for canine cell line validation","volume":"23","author":"O\u2019Donoghue","year":"2011","journal-title":"J Vet Diagn Invest"},{"issue":"7","key":"10.1016\/j.jpet.2025.103715_bib35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"issue":"46r","key":"10.1016\/j.jpet.2025.103715_bib36","article-title":"ImageJ user guide","volume":"IJ 1","author":"Ferreira","year":"2011","journal-title":"National Institutes of Health"},{"key":"10.1016\/j.jpet.2025.103715_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.jpet.2025.103715_bib40","series-title":"A computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 values","first-page":"1","article-title":"CompuSyn For Drug Combinations User\u2019s Guide","author":"Chou","year":"2004"},{"key":"10.1016\/j.jpet.2025.103715_bib41","author":"Chou"},{"issue":"12","key":"10.1016\/j.jpet.2025.103715_bib44","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1002\/1097-0142(19930615)71:12<3926::AID-CNCR2820711221>3.0.CO;2-2","article-title":"Proliferation index as a prognostic marker in breast cancer","volume":"71","author":"Veronese","year":"1993","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jpet.2025.103715_bib45","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00280-021-04325-y","article-title":"Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma","volume":"88","author":"Gustafson","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103715_bib46","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.immuni.2015.10.015","article-title":"The FOXO1 transcription factor instructs the germinal center dark zone program","volume":"43","author":"Dominguez-Sola","year":"2015","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.jpet.2025.103715_bib47","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.immuni.2015.10.021","article-title":"PI3 kinase and FOXO1 transcription factor activity differentially control B cells in the germinal center light and dark zones","volume":"43","author":"Sander","year":"2015","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.jpet.2025.103715_bib50","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1354\/vp.39-2-240","article-title":"Prognostic significance of a new histologic grading system for canine osteosarcoma","volume":"39","author":"Kirpensteijn","year":"2002","journal-title":"Vet Pathol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103715_bib51","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5326\/15473317-32-3-257","article-title":"Canine mandibular osteosarcoma: 51 cases (1980-1992)","volume":"32","author":"Straw","year":"1996","journal-title":"J Am Anim Hosp Assoc"},{"issue":"6","key":"10.1016\/j.jpet.2025.103715_bib53","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1939-1676.2000.tb02281.x","article-title":"Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma","volume":"14","author":"Garzotto","year":"2000","journal-title":"J Vet Intern Med"},{"issue":"6","key":"10.1016\/j.jpet.2025.103715_bib54","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1939-1676.2010.0591.x","article-title":"Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma","volume":"24","author":"Sottnik","year":"2010","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jpet.2025.103715_bib55","series-title":"Phase-I clinical trial of the dual PI3K\/mTOR inhibitor VDC-597 in dogs with spontaneous neoplasia. Slides presented at: ACVIM Annual Forum","author":"Thamm","year":"2018"},{"key":"10.1016\/j.jpet.2025.103715_bib56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1746-6148-8-56","article-title":"Prognostic factors in canine appendicular osteosarcoma - a meta-analysis","volume":"8","author":"Boerman","year":"2012","journal-title":"BMC Vet Res"},{"key":"10.1016\/j.jpet.2025.103715_bib57","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jcpa.2023.08.007","article-title":"Activation of the Akt signalling pathway as a prognostic indicator in canine soft tissue sarcoma","volume":"206","author":"Miyanishi","year":"2023","journal-title":"J Comp Pathol"},{"key":"10.1016\/j.jpet.2025.103715_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215660","article-title":"PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma","volume":"536","author":"Chen","year":"2022","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.jpet.2025.103715_bib59","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ygyno.2021.06.015","article-title":"Synergistic effects of a combined treatment of PI3K\/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma","volume":"162","author":"Jia","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103715_bib60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3892\/mmr.2021.11940","article-title":"Dual PI3K\/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells","volume":"23","author":"Li","year":"2021","journal-title":"Mol Med Rep"},{"issue":"9","key":"10.1016\/j.jpet.2025.103715_bib61","first-page":"2713","article-title":"The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro","volume":"31","author":"Liu","year":"2011","journal-title":"Anticancer Res"},{"issue":"11","key":"10.1016\/j.jpet.2025.103715_bib62","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/13543784.2019.1676726","article-title":"Targeting AKT for cancer therapy","volume":"28","author":"Shariati","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jpet.2025.103715_bib63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2016.11.024","article-title":"Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response","volume":"388","author":"Xie","year":"2017","journal-title":"Cancer Lett"},{"issue":"7","key":"10.1016\/j.jpet.2025.103715_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200634","article-title":"In vitro effects of PI3K\/mTOR inhibition in canine hemangiosarcoma","volume":"13","author":"Pyuen","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2025.103715_bib65","first-page":"376","article-title":"Reduction-responsive nucleic acid nanocarrier-mediated miR-22 inhibition of PI3K\/AKT pathway for the treatment of patient-derived tumor xenograft osteosarcoma","volume":"28","author":"Chen","year":"2023","journal-title":"Bioact Mater"},{"issue":"9","key":"10.1016\/j.jpet.2025.103715_bib66","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/1535-7163.MCT-07-0155","article-title":"The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion","volume":"6","author":"Hjelmeland","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jpet.2025.103715_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154902","article-title":"New emerging targets in osteosarcoma therapy: PTEN and PI3K\/Akt crosstalk in carcinogenesis","volume":"251","author":"Sadrkhanloo","year":"2023","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jpet.2025.103715_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2024.106264","article-title":"Antitumor effects of inhibitors of ERK and Akt pathways in canine histiocytic sarcoma cell lines","volume":"308","author":"Sakuma","year":"2024","journal-title":"Vet J"},{"issue":"1","key":"10.1016\/j.jpet.2025.103715_bib69","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s10020-023-00722-6","article-title":"RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K\/AKT\/mTOR pathway","volume":"29","author":"Wei","year":"2023","journal-title":"Mol Med"},{"key":"10.1016\/j.jpet.2025.103715_bib70","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0065-230X(08)60862-3","article-title":"How tumors become angiogenic","volume":"69","author":"Bouck","year":"1996","journal-title":"Adv Cancer Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103715_bib71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1084\/jem.136.2.261","article-title":"Tumor dormancy in vivo by prevention of neovascularization","volume":"136","author":"Gimbrone","year":"1972","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.jpet.2025.103715_bib72","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.jpet.2025.103715_bib73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"10.1016\/j.jpet.2025.103715_bib74","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2174\/1871520619666181218164050","article-title":"Evaluation of angiogenesis process after metformin and LY294002 treatment in mammary tumor","volume":"19","author":"Moschetta","year":"2019","journal-title":"Anticancer Agents Med Chem"},{"issue":"7","key":"10.1016\/j.jpet.2025.103715_bib75","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3390\/jpm14070693","article-title":"Revolutionizing pathology with artificial intelligence: innovations in immunohistochemistry","volume":"14","author":"Poalelungi","year":"2024","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.jpet.2025.103715_bib76","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/joim.13030","article-title":"Artificial intelligence as the next step towards precision pathology","volume":"288","author":"Acs","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.jpet.2025.103715_bib77","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lfs.2017.11.030","article-title":"The regulation of FOXO1 and its role in disease progression","volume":"193","author":"Xing","year":"2018","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.jpet.2025.103715_bib78","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/vco.12680","article-title":"The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines","volume":"19","author":"Breitbach","year":"2021","journal-title":"Vet Comp Oncol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:58:58Z","timestamp":1761850738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0022356525402286"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103715","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphatidylinositol 3-kinase and mechanistic target of rapamycin dualinhibitor, VDC597, as a therapeutic agent for canine osteosarcoma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"103715"}}